Jomrich G, Schoppmann S F
a Department of Surgery, Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC) , Medical University of Vienna , Vienna , Austria.
Expert Rev Anticancer Ther. 2016;16(1):111-22. doi: 10.1586/14737140.2016.1121110. Epub 2015 Dec 5.
Gastric cancer is one of the most commonly diagnosed and the second leading cause of cancer death worldwide. Surgery combined with multimodal therapy remains the only curative therapy. However, local relapse or distant metastases occur in more than 50% of radically resected patients. Due to molecular therapies, targeting HER2 and angiogenesis, major advances in the treatment of gastric cancer could be achieved. Nevertheless, development of resistance to monoclonal antibodies, such as trastuzumab, is arising. Currently a number of promising new therapeutic are under investigation, combining chemotherapy with newly developed agents to overcome cancer resistance. In this review we report current clinical applications of targeted therapies and overview ongoing trials, investigating the use of monoclonal antibodies in (HER2 positive) gastric cancer.
胃癌是全球最常被诊断出的癌症之一，也是癌症死亡的第二大主要原因。手术联合多模式治疗仍然是唯一的治愈性疗法。然而，超过50%接受根治性切除的患者会出现局部复发或远处转移。由于针对HER2和血管生成的分子疗法，胃癌治疗取得了重大进展。尽管如此，对曲妥珠单抗等单克隆抗体的耐药性正在出现。目前，一些有前景的新疗法正在研究中，将化疗与新开发的药物联合使用以克服癌症耐药性。在本综述中，我们报告了靶向治疗的当前临床应用，并概述了正在进行的试验，这些试验研究了单克隆抗体在（HER2阳性）胃癌中的应用。
